There are currently 10 ongoing clinical trials involving Friedreich Ataxia
Of the 10 trials,5 trials are in Phase II
Furthermore, 3 trials are in Phase II/III
The global pharmaceutical industry is steadily developing new drugs for Friedreich Ataxia, a Central Nervous System disorder. The largest number of ongoing clinical trials for Friedreich Ataxia is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Friedreich Ataxia-related drug trials.
Friedreich Ataxia related clinical trial sponsor
PTC Therapeutics Inc , Reata Pharmaceuticals Inc, Stealth Biotherapeutics Corp, C-TRI Co Ltd, and Metro International Biotech LLC are a few notable clinical trial sponsors involved in Friedreich Ataxia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Friedreich Ataxia
Idebenone (Ideben) is the sole key marketed drugs involving Friedreich Ataxia.
Idebenone (Ideben) is a benzoquinone derivative and synthetic analogue of ubiquinone, acts as a potent antioxidant. Idebenone (Ideben) is formulated as film-coated tablets for oral route of administration. Ideben is indicated for the treatment of vascular and degenerative diseases of the central nervous system including chronic cerebrovascular diseases, stroke, Alzheimer’s disease, dementia, cognitive impairment, Friedreich’s ataxia and excitatory amino acid (EAA) neuro toxicity (Leber's optic neuropathy). Idebenone is marketed solely in India by Exeltis - Ordain Health Care Global Pvt Ltd.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer